SLDB SEC Filing News — Solid Biosciences Inc.

Latest SEC filings for Solid Biosciences Inc. (SLDB) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, wh…
Sector: Healthcare Industry: Biotechnology Market Cap: $634.8M
20
Total Filings
0
Bullish Classifications
0
Bearish Classifications
16
Insider Transactions
2
Material Events (8-K)
2
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Solid Biosciences Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
SLDB Filing Activity Snapshot 2026-04-21 — 2026-10-06
Insider Transactions (Form 4)
0 buys vs 0 sells
Insider buying and selling activity is balanced in this period.
Insider Transactions 16 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 16 filings in this group are Form 4s for Solid Biosciences Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 16 insider filings shown, the breakdown is 14 compensation award and 2 option exercise. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×14
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Option exercise Tax / Compensation Filing 2026-10-06

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

SMITH IAN F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 3,440 — —
M Option exercise derivative · Restricted Stock Units 3,440 — —
Filing: Form 4 (Insider Transaction) Insider: SMITH IAN F (Director) Shares: 3,440
Form 4 Option exercise Tax / Compensation Filing 2026-07-07

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

SMITH IAN F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 3,440 — —
M Option exercise derivative · Restricted Stock Units 3,440 — —
Filing: Form 4 (Insider Transaction) Insider: SMITH IAN F (Director) Shares: 3,440
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Nagendran Sukumar (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Nagendran Sukumar (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

SMITH IAN F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: SMITH IAN F (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Ganot Ilan (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Ganot Ilan (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

PERCEPTIVE ADVISORS LLC (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: PERCEPTIVE ADVISORS LLC (Director, 10% Owner)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Keresty Georgia (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Keresty Georgia (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Freed Martin I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Freed Martin I (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Kahn Clare (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Kahn Clare (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Sullivan Lynne Marie (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Sullivan Lynne Marie (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-06-11

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Stone Adam Leo (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 77,500 — —
Filing: Form 4 (Insider Transaction) Insider: Stone Adam Leo (Director)
Form 4 Compensation award Tax / Compensation Filing 2026-04-21

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Howton David T (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 79,341 — —
Filing: Form 4 (Insider Transaction) Insider: Howton David T (Chief Operating Officer)
Form 4 Compensation award Tax / Compensation Filing 2026-04-21

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Brooks Gabriel (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 58,847 — —
Filing: Form 4 (Insider Transaction) Insider: Brooks Gabriel (Chief Medical Officer)
Form 4 Compensation award Tax / Compensation Filing 2026-04-21

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Cumbo Alexander (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 169,401 — —
Filing: Form 4 (Insider Transaction) Insider: Cumbo Alexander (Director, President and CEO)
Form 4 Compensation award Tax / Compensation Filing 2026-04-21

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Herzich Paul (Chief Technology Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 54,925 — —
Filing: Form 4 (Insider Transaction) Insider: Herzich Paul (Chief Technology Officer)
Form 4 Compensation award Tax / Compensation Filing 2026-04-21

SLDB insider Form 4 filed for equity award, exercise, or tax withholding

Tan Kevin (CFO & Treasurer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 56,647 — —
Filing: Form 4 (Insider Transaction) Insider: Tan Kevin (CFO & Treasurer)
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Solid Biosciences Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06

SLDB filed 8-K — material company event

Solid Biosciences Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-06-10

SLDB filed 8-K — material company event

Solid Biosciences Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 quarterly reports (10-Q) for Solid Biosciences Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

SLDB filed Quarterly Report (10-Q)

Solid Biosciences Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-Q Quarterly Report 2026-05-12

SLDB filed Quarterly Report (10-Q)

Solid Biosciences Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

How we classify Solid Biosciences Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on SLDB. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — SLDB SEC Filings

More Tools for SLDB

Want deeper SLDB analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the SLDB stock analysis page.

SLDB Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer